Washington Reporter

Washington Reporter

Share this post

Washington Reporter
Washington Reporter
FTC facing lawsuit and criticism over its handling of Pharmacy Benefit Managers (PBMs)
Copy link
Facebook
Email
Notes
More
Editorials

FTC facing lawsuit and criticism over its handling of Pharmacy Benefit Managers (PBMs)

The FTC’s handling of PBMs is only the latest issue where the Lina Khan-controlled FTC has led to legal challenges for the Biden-Harris administration.

Matthew Foldi's avatar
Matthew Foldi
Sep 23, 2024

Share this post

Washington Reporter
Washington Reporter
FTC facing lawsuit and criticism over its handling of Pharmacy Benefit Managers (PBMs)
Copy link
Facebook
Email
Notes
More
Share

President Joe Biden’s Federal Trade Commission (FTC) is facing a lawsuit and heavy criticism from conservatives over the commission’s years-long aggressive action against pharmacy benefit managers (PBMs). The FTC continued its actions against PBMs with a lawsuit over insulin prices announced on Friday. 

The FTC’s handling of PBMs is only the latest issue where the Lina Khan-controlled FTC has led to legal challenges for the Biden-Harris administration. 

The FTC announced an inquiry into PBMs — the companies that are hired by employers and health insurance plans to negotiate with pharmaceutical manufacturers for lower drug costs — in 2022. Health care experts considered the  FTC’s action against PBMs unusual because it was a reversal of a decades-long stance by the FTC that PBMs lead to lower drug costs. 

Conservatives criticized the FTC for the reversal, and argued that the decision was politicized and driven by politics instead of policy, resulting in an ethics complaint against Khan by conservative watchdog, the American Accountability Foundation (AAF).

Now, the FTC faces a major lawsuit from Express Scripts, one of the largest PBMs, over a 2024 FTC interim report that criticized PBMs. The lawsuit argues that the interim report “followed prejudice and politics” instead of policy, and failed to acknowledge the evidence that “PBMs lower prescription drug costs for health plan sponsors (employers, unions, and governments) who use PBMs to negotiate with (among others) pharmaceutical manufacturers and retail pharmacies to drive cost savings.”

This lawsuit follows extensive criticism from conservatives on the FTC’s treatment of PBMs. Former Secretary of State Mike Pompeo said that “President Biden’s FTC Commissioners published a biased and deeply flawed report on pharmacy benefit managers (PBMs). The facts and data show that PBMs lower costs for patients. That’s why employers overwhelmingly use them. But all this administration cares about is growing its own power.”

Joel Zinburg from the Competitive Enterprise Institute recently criticized Khan’s “evidence-free interim report, which she has threatened could form the basis of future prosecutions.” Zinburg sees it as a continuation of Khan’s “shoddy work in pursuit of antitrust overreach.”

Khan’s actions against PBMs come following a string of legal defeats she’s suffered. Recently, her actions on non-competes had “no basis in law”; the Wall Street Journal noted that while “Federal Trade Commission Chair Lina Khan is a heroine to the media, [she is] not to federal judges, who keep ruling against her antitrust cases.”

Khan’s anti-consolidation actions “concretely jeopardiz[ed] Biden’s already-unlikely promise to cure cancer,” as The Spectator reported. 

A House Leadership aide told the Reporter that “Lina Khan is trying to do Kamala Harris a favor with her obsessing over PBMs, but it’s just politics. No one is falling for this.”


Subscribe to Washington Reporter

The intersection of policy and politics, with valuable insights straight from Hill staff and D.C. insiders.

Share this post

Washington Reporter
Washington Reporter
FTC facing lawsuit and criticism over its handling of Pharmacy Benefit Managers (PBMs)
Copy link
Facebook
Email
Notes
More
Share
Why the Biden Pill Penalty has been a disaster for Americans
A misguided policy enacted by former President Joe Biden has led to a 70 percent decline in investment in small-molecule drugs in the United States…
Mar 20 • 
The Washington Reporter
3

Share this post

Washington Reporter
Washington Reporter
Why the Biden Pill Penalty has been a disaster for Americans
Copy link
Facebook
Email
Notes
More
EXCLUSIVE: Multiple career intelligence staff confirm Biden admin DNI Avril Haines used Signal "all the time and on her personal phone"
Biden administration Director of National Intelligence (DNI) Avril Haines used Signal “all the time and on her personal phone,” according to multiple…
Apr 3 • 
Matthew Foldi
11

Share this post

Washington Reporter
Washington Reporter
EXCLUSIVE: Multiple career intelligence staff confirm Biden admin DNI Avril Haines used Signal "all the time and on her personal phone"
Copy link
Facebook
Email
Notes
More
Op-Ed: Rep. Mike Haridopolos: Take Donald Trump’s Greenland gambit seriously
President Donald Trump has the opportunity to make the deal of the century in the Arctic, Rep. Mike Haridopolos explains. Here's why it's needed.
Jan 10 • 
The Washington Reporter
13

Share this post

Washington Reporter
Washington Reporter
Op-Ed: Rep. Mike Haridopolos: Take Donald Trump’s Greenland gambit seriously
Copy link
Facebook
Email
Notes
More

Ready for more?

© 2025 Washington Reporter
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share

Copy link
Facebook
Email
Notes
More